J&J-Immunicon Dispute Highlights Challenges Of Exclusive Agreements
This article was originally published in The Gray Sheet
Executive Summary
A sales and marketing relationship gone sour between cancer diagnostic developer Immunicon and a Johnson & Johnson subsidiary illustrates the risks firms take when choosing an exclusive distributor